| Bioactivity | Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease[1][2]. |
| Invitro | Sotrovimab 可以中和 SARS-CoV-2 和 SARS-CoV，但不能直接阻断病毒受体结合[2]。Sotrovimab (100 μg/mL, 注射入培养基, 持续 200 s, v=30 μL/min) 能有效结合表面表达的 SARS-CoV-2 S[3]。Sotrovimab (0.3 ng/mL-20 mg/mL; 30 min) 对 SARS-CoV-2 伪型病毒具有体外中和作用，对Alpha、Beta、Gamma、Delta 和 Kappa 变种病毒的 IC50 分别为 187.2 ng/mL、71.9 ng/mL、73.11 ng/mL、51.3 ng/mL 和 118.64 ng/mL[3]。 |
| In Vivo | Sotrovimab (5 mg/kg, 10 mL; 经静脉导管给药; 单次剂量) 可对雌性食蟹猴肺部的易感变异进行长达 28 天的保护性暴露[3]。 |
| Name | Sotrovimab |
| CAS | 2423014-07-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gupta A, et al; COMET-ICE Investigators. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021 Nov 18;385(21):1941-1950. [2]. Case JB, et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat Commun. 2022 Jul 2;13(1):3824. [3]. Cathcart A L, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2[J]. biorxiv, 2022: 2021.03. 09.434607. [4]. Aweda TA, et al. In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys. Eur J Nucl Med Mol Imaging. 2022 Oct 28:1–12. |